Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Hematology Information Center

FDA Approval Expands Access of Artesunate for Malaria Treatment

Diana Ernst, RPh

May 29, 2020

The FDA has approved Artesunate for Injection (Amivas) for the initial treatment of severe malaria in adult and pediatric patients.

Infectious Diseases Information Center

NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated

Diana Ernst, RPh

May 13, 2020

Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.

Vaccine Information Center

AAP: Declines in Immunization During COVID-19 Pandemic Concerning

Diana Ernst, RPh

May 12, 2020

The AAP has issued a statement regarding recent data published by the Centers for Disease Control and Prevention (CDC) about a decline in pediatric vaccination during the COVID-19 pandemic.

Infectious Diseases Information Center

FDA Urges Recovered COVID-19 Patients to Donate Plasma

Diana Ernst, RPh

May 1, 2020

The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.

Psychiatry Information Center

FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19

Diana Ernst, RPh

April 29, 2020

The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.

Infectious Diseases Information Center

Joint Statement Issued on Reducing Arrhythmia Risk With COVID-19 Repurposed Drugs

Diana Ernst, RPh

April 10, 2020

Although not approved by the Food and Drug Administration (FDA) for COVID-19, hydroxychloroquine and azithromycin have been gaining momentum as potential treatments based on results of small studies.

Hematology Information Center

FDA Allows Use of COVID-19 Convalescent Plasma for Severely Ill Patients Under Emergency IND

Diana Ernst, RPh

April 8, 2020

Convalescent plasma, which is collected from patients who have recovered from COVID-19, contains antibodies to SARS-CoV-2, the virus that causes the disease.

Infectious Diseases Information Center

Drug Shortages Reported as New Program Created to Expedite Treatments for COVID-19

Diana Ernst, RPh

April 7, 2020

To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.

Infectious Diseases Information Center

ACAAI: Statement on Corticosteroid Use for Allergies, Asthma During COVID-19 Pandemic

Diana Ernst, RPh

April 3, 2020

The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.